FDA Approves Trodelvy, Breakthrough Treatment For Breast Cancer
Phase 3 trials showed Trodelvy cut disease progression or death risk by 38% in patients not eligible for immunotherapy, Gilead Sciences said.
- On June 24, the U.S. Food and Drug Administration expanded approval for Trodelvy as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer , Gilead Sciences announced.
- Triple-Negative breast cancer lacks standard estrogen, progesterone, and HER2 protein targets, making it aggressive and difficult to treat compared to other breast cancer subtypes.
- Clinical trials showed that Trodelvy-based treatments reduced disease progression risk by 38% compared with chemotherapy alone, targeting the Trop-2 protein found on more than 90% of breast cancer cells.
- The National Comprehensive Cancer Network now recommends Trodelvy, with or without Keytruda, as a Category 1 preferred first-line treatment, giving doctors greater flexibility to tailor therapy.
- For Black women, who face a 42% higher mortality rate, Co-Founder and CEO of The Black Breast Cancer Alliance Ricki Fairley emphasizes that this advancement offers renewed hope to a community long underserved by traditional therapies.
11 Articles
11 Articles
Black America Web
FDA Approves Trodelvy, A Breakthrough Treatment For One Of The Deadliest Breast Cancers
Source: stefanamer / Getty A groundbreaking new treatment is giving fresh hope to people diagnosed with one of the most aggressive forms of breastcancer. The U.S. Food and Drug Administration (FDA) has approved Trodelvy, a chemotherapy medicine that can now be used as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer(mTNBC). The milestone marks a major advancement for patients facing…
FDA Approves Trodelvy, Breakthrough Treatment For Breast Cancer
Source: stefanamer / Getty A groundbreaking new treatment is giving fresh hope to people diagnosed with one of the most aggressive forms of breastcancer. The U.S. Food and Drug Administration (FDA) has approved Trodelvy, a chemotherapy medicine that can now be used as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer(mTNBC). The milestone marks a major advancement for patients facing…
FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers
Source: stefanamer / Getty A groundbreaking new treatment is giving fresh hope to people diagnosed with one of the most aggressive forms of breast cancer. The U.S. Food and Drug Administration (FDA) has approved Trodelvy, a chemotherapy medicine that can now be used as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). The milestone marks a major advancement for patients faci…
BLK ALERTS - FDA Approves Trodelvy, A Breakthrough Treatment For One Of The Deadliest Breast Cancers
Source: stefanamer / Getty A groundbreaking new treatment is giving fresh hope to people diagnosed with one of the most aggressive forms of breastcancer. The U.S. Food and Drug Administration (FDA) has approved Trodelvy, a chemotherapy medicine that can now be used as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer(mTNBC). The milestone marks a major advancement for patients facing…
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
